FDA Expands Auryxia Indication to CKD Patients Not on Dialysis FDA Expands Auryxia Indication to CKD Patients Not on Dialysis

With the expanded indication, Auryxia is now the first and only oral treatment available to treat iron deficiency anemia in patients with non-dialysis-dependent CKD, the company said.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Alert Source Type: news